Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04477785 · ClinicalTrials.gov registry record

PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort

A clinical trial of Parkinson Disease, sponsored by Michael J. Fox Foundation for Parkinson's Research.

Recruiting
Registry status
4,500
Enrollment target
20
Study locations

NCT04477785: Recruiting study of Parkinson Disease, sponsored by Michael J. Fox Foundation for Parkinson's Research.

NCT04477785 is a study of Parkinson Disease that is actively recruiting participants, run by Michael J. Fox Foundation for Parkinson's Research. The registered enrollment target is 4,500 participants, below the 5,311-participant average among 297 other Parkinson Disease trials with a reported enrollment target (15% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04477785, a study of Parkinson Disease, is actively recruiting participants, sponsored by Michael J. Fox Foundation for Parkinson's Research.

RECRUITING
Registry status
4,500 participants
Enrollment target
20
Study locations

Study Summary

The Parkinson Progression Marker Initiative (PPMI) is a longitudinal, observational, multi-center natural history study to assess progression of clinical features, digital outcomes, and imaging, biologic and genetic markers of Parkinson's disease (PD) progression in study participants with manifest PD, prodromal PD, and healthy controls. The overall goal of PPMI is to identify markers of disease progression for use in clinical trials of therapies to reduce progression of PD disability.

Primary Outcome

This protocol will build on the existing PPMI infrastructure

Conditions Studied

Parkinson Disease

Study Locations (20)

Arizona

  • Barrow Neurological Institute - Phoenix
  • Mayo Foundation for Medical Education and Research - Scottsdale
  • Banner Research Institute - Sun City

California

  • University of California San Diego - La Jolla
  • Keck School of Medicine of USC - Los Angeles
  • University of California, San Francisco - San Francisco

Florida

  • Parkinson's Disease& Movement Disorder Center of Boca Raton - Boca Raton
  • University of Florida - Gainesville
  • University of South Florida - Tampa

Massachusetts

  • Boston University - Boston
  • Massachusetts General Hospital - Boston

Alabama

  • University of Alabama at Birmingham - Birmingham

Colorado

  • University of Colorado Anschutz Medical Campus - Aurora

Connecticut

  • Institute For Neurodegenerative Disorders - New Haven

Georgia

  • Emory University School of Medicine - Atlanta

Trial Details

FieldValue
Enrollment Target 4,500 participants
Start Date 2020-07-01
Est. Completion 2033-12
Michael J. Fox Foundation for Parkinson's Research

14 total trials

What NCT04477785 shows while recruiting

NCT04477785 is an observational study that tracks outcomes without assigning an intervention. Its 4,500 participants enrollment target places it among the larger protocols in the corpus, below the 5,311-participant average among 297 other Parkinson Disease trials with a reported enrollment target (15% lower).

The record links to 1 condition, with Parkinson Disease appearing as the primary indexed condition, and to 0 interventions.

NCT04477785 names 20 study sites across 13 states, led by Arizona, California, Florida.

Frequently Asked Questions

What is clinical trial NCT04477785 about?

NCT04477785 is a clinical study titled "PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort". The Parkinson Progression Marker Initiative (PPMI) is a longitudinal, observational, multi-center natural history study to assess progression of clinical features, digital outcomes, and imaging, biologic and genetic markers of Parkinson's disease (PD) progression in study participants with manifest ...

What is the current status of trial NCT04477785?

This trial is currently recruiting. The enrollment target is 4,500 participants. The study started on 2020-07-01. Estimated completion is 2033-12.

What conditions does trial NCT04477785 study?

This clinical trial studies the following conditions: Parkinson Disease.

Who is sponsoring clinical trial NCT04477785?

This trial is sponsored by Michael J. Fox Foundation for Parkinson's Research, which has 14 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04477785 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Parkinson Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04477785's enrollment target sits among peer trials

4,500 6th of 297 higher than 292 of 297 other Parkinson Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Parkinson Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06533111 · 4,500 participants · NA

    Improving Surgical Patient Outcomes Through Implementation of a SemiStructured Intraoperative Anesthesia Handoff Tool

  • NCT06588452 · 4,500 participants

    Manual Versus AI-Assisted Clinical Trial Screening Using Large-Language Models

  • NCT07165028 · 4,500 participants · Phase 3

    A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

  • NCT07207564 · 4,500 participants

    Integrating Molecular Pathology, Radiology, and Genetics to Improve Breast Cancer Risk

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT04477785

Source: ClinicalTrials.gov NCT04477785, the US trial registry maintained by the National Library of Medicine. NCT04477785 (large enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.